Timing of of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer

被引:48
作者
Gao, Sarah J. [1 ]
Corso, Christopher D. [1 ]
Wang, Elyn H. [1 ]
Blasberg, Justin D. [2 ]
Detterbeck, Frank C. [2 ]
Boffa, Daniel J. [2 ]
Decker, Roy H. [1 ]
Kim, Anthony W. [2 ]
机构
[1] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06510 USA
[2] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA
关键词
NSCLC; Trimodality therapy; Chemotherapy; Radiation therapy; Surgery; Survival; PULMONARY-FUNCTION TESTS; RADIATION PNEUMONITIS; PREOPERATIVE CHEMOTHERAPY; PHASE-II; INDUCTION CHEMOTHERAPY; RANDOMIZED-TRIAL; RADIOTHERAPY; THERAPY; DISPARITIES; CISPLATIN;
D O I
10.1016/j.jtho.2016.09.122
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: A subset of patients with potentially resectable clinical stage IIIA NSCLC are managed with trimodality therapy. However, little data exist to guide the timing of surgery after neoadjuvant therapy: This study examined whether the time interval between neoadjuvant chemoradiation (NCRT) and surgical resection affects overall survival. Methods: Patients with clinical stage IIIA disease (T1-3 N2) NSCLC who underwent NCRT were identified in the National Cancer Data Base (NCDB) between 2004 and 2012 and categorized on the basis of the interval between chemoradiation and surgery (0 to <= 3, >3 to <= 6, >6 to <= 9, and >9 to <= 12 weeks). Other clinical stages were excluded. The Kaplan-Meier method and log-rank tests were used to compare overall survival rates, and a bootstrapped Cox proportional hazards model was used to determine significant contributors to overall survival. Results: Of the 1623 patients identified, 7.9% underwent an operation 0 to 3 weeks or less after NCRT, 50.5% underwent an operation greater than 3 and less than or equal to 6 weeks after NCRT, 31.9% underwent an operation greater than 6 and less than or equal to 9 weeks after NCRT, and 9.6% underwent an operation greater than 9 and less than or equal to 12 weeks after NCRT. Multivariate survival analysis demonstrated no significant difference in survival in those who underwent an operation within 6 weeks of NCRT. However, significant drops in overall survival were observed in those who had an operation greater than 6 and less than or equal to 9 weeks after NCRT (hazard ratio = 1.33, 95% confidence interval: 1.01-1.76, p = 0.043) and greater than 9 and less than or equal to 12 weeks after NCRT (hazard ratio = 1.44, 95% confidence interval: 1.04-2.01, p = 0.030). Conclusions: The findings from this retrospective study suggest that overall survival may be significantly lower in patients with clinical stage IIIA N2 NSCLC who undergo an operation later than 6 weeks after NCRT. discourage unnecessary delays in surgery. (C) 2016 International Association for the Cancer. Published by Elsevier Inc. All rights These results Study of Lung reserved.
引用
收藏
页码:314 / 322
页数:9
相关论文
共 35 条
[1]   Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].
Albain, Kathy S. ;
Swann, R. Suzanne ;
Rusch, Valerie W. ;
Turrisi, Andrew T., III ;
Shepherd, Frances A. ;
Smith, Colum ;
Chen, Yuhchyau ;
Livingston, Robert B. ;
Feins, Richard H. ;
Gandara, David R. ;
Fry, Willard A. ;
Darling, Gail ;
Johnson, David H. ;
Green, Mark R. ;
Miller, Robert C. ;
Ley, Joanne ;
Sause, Willliam T. ;
Cox, James D. .
LANCET, 2009, 374 (9687) :379-386
[2]   CONCURRENT CISPLATIN/ETOPOSIDE PLUS CHEST RADIOTHERAPY FOLLOWED BY SURGERY FOR STAGES IIIA(N2) AND IIIB NON-SMALL-CELL LUNG-CANCER - MATURE RESULTS OF SOUTHWEST-ONCOLOGY-GROUP PHASE-II STUDY-8805 [J].
ALBAIN, KS ;
RUSCH, VW ;
CROWLEY, JJ ;
RICE, TW ;
TURRISI, AT ;
WEICK, JK ;
LONCHYNA, VA ;
PRESANT, CA ;
MCKENNA, RJ ;
GANDARA, DR ;
FOSMIRE, H ;
TAYLOR, SA ;
STELZER, KJ ;
BEASLEY, KR ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :1880-1892
[3]   Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline [J].
Bezjak, Andrea ;
Temin, Sarah ;
Franklin, Gregg ;
Giaccone, Giuseppe ;
Govindan, Ramaswamy ;
Johnson, Melissa L. ;
Rimner, Andreas ;
Schneider, Bryan J. ;
Strawn, John ;
Azzoli, Christopher G. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) :2100-U162
[4]   Higher Versus Standard Preoperative Radiation in the Trimodality Treatment of Stage IIIa Lung Cancer [J].
Bharadwaj, Steven C. ;
Vallieres, Eric ;
Wilshire, Candice L. ;
Blitz, Maurice ;
Page, Brandi ;
Aye, Ralph W. ;
Farivar, Alexander S. ;
Louie, Brian E. .
ANNALS OF THORACIC SURGERY, 2015, 100 (01) :207-214
[5]   The National Cancer Data Base: A powerful initiative to improve cancer care in the United States [J].
Bilimoria, Karl Y. ;
Stewart, Andrew K. ;
Winchester, David P. ;
Ko, Clifford Y. .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (03) :683-690
[6]   Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer [J].
Bujko, K. ;
Nowacki, M. P. ;
Nasierowska-Guttmejer, A. ;
Michalski, W. ;
Bebenek, M. ;
Kryj, M. .
BRITISH JOURNAL OF SURGERY, 2006, 93 (10) :1215-1223
[7]   Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial [J].
Burkes, RL ;
Shepherd, FA ;
Blackstein, ME ;
Goldberg, ME ;
Waters, PF ;
Patterson, GA ;
Todd, T ;
Pearson, FG ;
Jones, D ;
Farooq, S ;
McGlaughlin, J ;
Ginsberg, RJ .
LUNG CANCER, 2005, 47 (01) :103-109
[8]   How does radiation kill cells? [J].
Cohen-Jonathan, E ;
Bernhard, EJ ;
McKenna, WG .
CURRENT OPINION IN CHEMICAL BIOLOGY, 1999, 3 (01) :77-83
[9]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[10]   Chemoradiation for Definitive, Preoperative, or Postoperative Therapy of Locally Advanced Non-Small Cell Lung Cancer [J].
Feliciano, Josephine ;
Feigenberg, Steven ;
Mehta, Minesh .
CANCER JOURNAL, 2013, 19 (03) :222-230